原标题："中保"观察 | 从头部险企健康险理赔"结构"，看实际保障力度被低估 来源：中保新知 今年过年不送礼，送礼就要送健康。关于健康的祝福，已成为挂在每一个人嘴边的口头禅。马年春节前 后，健康保障、健康管理也已经成为宏观经济与民生领域的热点话题。 其一是北京市医保局、金融监管总局北京监管局等九部门于2月联合印发《北京市支持商业健康保险高 质量发展的若干措施》，从产品创新、数据共享到医保商保协同，全方位为商业健康险高质量发展保驾 护航；其二是马年央视春晚上，健康AI应用"蚂蚁阿福"的高调亮相，也在加速推动健康管理进入全民视 野。 在政策与科技的双轮驱动下，大众对健康的关注热情持续攀升。那么，作为重要的健康保障工具，商业 健康险的发展现状如何，行业理赔力度怎样？近期金融监管总局披露的保险业务数据，以及人身险公司 相继出炉的年度理赔报告，或是解读商业健康险发展、观测理赔服务的重要窗口。 01 业务增速放缓 最新数据显示，2025年商业健康险保费为9973亿元，同比增幅2.04%，距离业内期待的万亿保费规模仅 一步之遥。剖析商业健康险"万亿"大关期待落差的原因，有业内人士直言，这背后主要受人身险公司健 康险业务小幅 ...

Core Viewpoint - The article discusses the challenges and opportunities in the commercial health insurance market in China, particularly focusing on cancer recurrence insurance, amidst the backdrop of rising out-of-pocket expenses for cancer treatment and the evolving healthcare landscape [2][3]. Group 1: Market Dynamics - China's healthcare insurance system has made significant progress in coverage, but patients still face high out-of-pocket costs, with some cancer treatments having self-payment ratios nearing or exceeding 50% [2]. - The demand for commercial health insurance, particularly for cancer patients, is increasing as the "cancer survivor" population grows [2]. - Commercial health insurance products, such as million medical insurance, primarily serve those who fall ill after purchasing the policy, while few products accept patients with a history of cancer [2][4]. Group 2: Product Development Challenges - The development of specialized disease insurance, such as cancer recurrence insurance, faces difficulties in product design and pricing, with a significant gap between market expectations and actual growth [4][5]. - Specialized disease insurance is tailored for specific patient groups, but the market for such products is still relatively small, with only a few billion in scale compared to hundreds of billions for broader medical insurance [4][5]. - The pricing of recurrence insurance is complicated by the need to balance affordability for patients with the necessity of covering potential risks [5][6]. Group 3: Sales and Distribution Issues - The primary challenge for insurance companies is not just pricing but also effectively reaching consumers to sell these products [6]. - Traditional sales channels are limited, and the online sales of recurrence insurance are rare, complicating the distribution process [6][7]. - The small target population for recurrence insurance, such as the estimated 6,000 breast cancer recurrence cases in Shanghai annually, makes it difficult to achieve significant sales volume [6][7]. Group 4: Collaboration and Data Utilization - Successful operation of specialized insurance products requires collaboration with hospitals and pharmaceutical companies to ensure patients receive timely and appropriate treatment [7][8]. - Access to comprehensive patient data from medical institutions is crucial for developing effective insurance products, as it helps in assessing risks and setting premiums [9][10]. - Recent policy changes in Shanghai have begun to facilitate data sharing between medical institutions and insurance companies, which could enhance the development of specialized insurance products [9][10][11]. Group 5: Future Outlook - The market for recurrence insurance is expected to grow, but its expansion will depend on the ability to cover more types of cancer and other diseases with similar recurrence risks [12][13]. - The collaboration between insurance companies and healthcare providers is essential for creating a sustainable model that benefits all parties involved, including patients, hospitals, and pharmaceutical companies [12][13].

Core Viewpoint - The article discusses the challenges and opportunities in the commercial health insurance market, particularly focusing on cancer recurrence insurance, as patients increasingly seek additional coverage due to high out-of-pocket costs despite improvements in the national healthcare system [3][4]. Group 1: Market Dynamics - The self-payment ratio for cancer treatment in China has reached or exceeded 50%, prompting patients to consider commercial health insurance [3]. - The growth rate of premium scale in the health insurance sector is below market expectations, leading to a search for new growth areas, particularly in niche products like cancer recurrence insurance [3][4]. - Commercial health insurance companies face difficulties in product design and pricing, with many newly launched products struggling to sell [4][5]. Group 2: Product Development Challenges - Specialized disease insurance, such as cancer recurrence insurance, is still in its infancy, with a market size of only a few billion compared to hundreds of billions for broader medical insurance [6]. - The development of recurrence insurance is complicated by the need to accurately predict disease recurrence rates and survival rates, which affects pricing and market acceptance [7][10]. - The insurance industry must balance the need for affordable premiums with comprehensive coverage, leading to conservative product designs [7][10]. Group 3: Sales and Distribution Issues - The primary challenge for insurance companies is not pricing but effectively reaching consumers, as traditional sales channels are limited [9][10]. - The small target population for recurrence insurance, such as the estimated 6,000 annual breast cancer recurrence cases in Shanghai, complicates sales efforts [9][10]. - High sales costs combined with low payout rates create a challenging environment for the recurrence insurance market [9][10]. Group 4: Data Utilization and Collaboration - Access to comprehensive patient data is crucial for designing effective cancer recurrence insurance products, necessitating collaboration with healthcare institutions [12][13]. - Recent regulatory changes in Shanghai have begun to facilitate data sharing between commercial insurers and healthcare providers, which is essential for product development [14][15]. - The collaboration between insurance companies and hospitals aims to enhance patient management and treatment outcomes, which could reduce future payout risks [10][14]. Group 5: Future Outlook - The recent easing of restrictions on insurance promotion within hospitals marks a significant step forward for the market, allowing for better product visibility and sales opportunities [15][16]. - The expansion of recurrence insurance will depend on the ability to cover more cancer types and other diseases with similar recurrence risks, presenting both opportunities and challenges for product development [17][18].

Core Viewpoint - Shanghai is planning a "breakthrough" initiative for collaboration between commercial insurance companies and medical institutions, focusing on cancer recurrence insurance as a key entry point [1][2] Group 1: Market Dynamics - The self-payment ratio for cancer treatment in China has reached or exceeded 50%, prompting patients to seek commercial health insurance [1] - The growth rate of premium scale in the health insurance sector is below market expectations, leading to a search for new growth areas, particularly in niche "pre-existing condition" insurance products like cancer recurrence insurance [1][3] - The market for specialized disease insurance, including cancer recurrence insurance, is still in its infancy, with only a few billion in market size compared to hundreds of billions for broader medical insurance [3] Group 2: Challenges in Product Development - The development of specialized disease insurance faces significant challenges in product design and pricing, with many products struggling to sell [1][3][5] - The insurance industry must navigate the complexities of pricing for recurrence insurance, which requires betting on disease recurrence rates and survival rates among patients [4][5] - The insurance products currently available tend to have conservative coverage designs due to affordability concerns [5] Group 3: Sales and Distribution Issues - The primary challenge for insurance companies is not pricing but rather how to effectively sell these products, as traditional sales channels are limited [6][11] - The small target population for cancer recurrence insurance, such as the estimated 6,000 breast cancer recurrence cases annually in Shanghai, complicates sales efforts [6][12] - The high sales costs and low payout rates in the insurance market further exacerbate the difficulties in selling recurrence insurance [6] Group 4: Collaboration with Medical Institutions - Successful implementation of recurrence insurance requires collaboration with hospitals and pharmaceutical companies to ensure patients receive timely and appropriate treatment [7][10] - Recent policy changes in Shanghai have allowed for pilot programs where commercial insurance can be promoted within hospitals, marking a significant shift in the market [11][12] - The integration of medical data from hospitals is crucial for developing effective recurrence insurance products, as it helps assess risk and set appropriate pricing [8][9][10] Group 5: Future Outlook - The expansion of the recurrence insurance market will depend on the ability to cover more types of cancer and other diseases with similar recurrence risks, such as cardiovascular diseases [12] - The development of specialized disease insurance products is closely tied to advancements in clinical medicine and biopharmaceutical technologies [12]

Core Viewpoint - The article discusses the recent measures introduced by the National Healthcare Security Administration and the National Health Commission to support the high-quality development of innovative drugs in China, marking a significant shift from a generic drug powerhouse to an innovative drug leader since 2015 [1][2]. Group 1: Policy Measures and Support - The "Measures" introduced on July 1 aim to enhance the entire chain of support for innovative drug development, including research, payment, and access [1][2]. - Regions such as the Yangtze River Delta and the Pearl River Delta have allocated substantial financial resources to support drug innovation, providing concrete measures across various aspects of drug development [2][3]. Group 2: Current Landscape of Innovative Drugs - China currently has 1,775 first-in-class drug pipelines, accounting for 19% of the global total, and holds 14% of the global license-out transactions, with 30% of the total value [2]. - The article highlights the challenges faced in the drug development cycle, particularly the long timelines and high costs associated with innovative drug research [3]. Group 3: Clinical Institutions and Innovation - Clinical institutions play a crucial role in identifying unmet clinical needs, and there is a call for more involvement in source innovation to enhance the development of first-in-class drugs [4]. - The need for a unified data platform and an internationally recognized evaluation system is emphasized to facilitate clinical research and innovation [4]. Group 4: Real-World Data and Application - The "Guangdong-Hong Kong-Macao Drug and Device Pass" policy has enabled the introduction of innovative drugs and devices in pilot hospitals, benefiting over 6,000 patients and generating valuable real-world data [5]. - Real-world studies are essential for accelerating drug development and regulatory approval, as demonstrated by the successful completion of a study on a novel migraine treatment [5]. Group 5: Overcoming Barriers to Access - Efforts are being made to address the "last mile" challenges in getting innovative drugs into hospitals, including the establishment of a digital innovation laboratory to enhance data collection and evaluation [6]. - The article discusses the importance of risk assessment and safety evaluations for innovative drugs, particularly in oncology, to build confidence among healthcare providers [6]. - The overall goal is to create a win-win situation where patients have access to innovative treatments, funding is sustainable, and companies are motivated to innovate [6].

Core Viewpoint - The commercial health insurance industry is increasingly focusing on insurance products for patients with pre-existing conditions, particularly in the context of disease recurrence insurance, which is expected to see significant growth by 2025 [3][4]. Group 1: Market Trends and Developments - The disease recurrence insurance market has seen new product launches, such as the "Good Effect Insurance" series by Taikang Online, which expanded coverage from breast cancer to include lymphoma and lung cancer [5]. - In 2024, the health insurance premium income reached 977.4 billion yuan, marking an 8.2% growth, but the industry is facing stagnation due to market saturation among healthy individuals [6][7]. - The concept of insuring patients with pre-existing conditions is still relatively new and unclear, with estimates suggesting that the market could be around 50 billion yuan, primarily driven by supplementary medical insurance and high-end medical insurance [9]. Group 2: Product Insights - The most notable products in the disease recurrence insurance category are breast cancer recurrence insurance, which has become the largest single product in this segment, and million medical insurance that covers pre-existing conditions [12]. - The "Zhongminbao" product by Zhong An Insurance achieved rapid success, collecting 1.4 billion yuan in premiums within ten days of launch, indicating strong market demand [12][13]. Group 3: Sales and Distribution Challenges - The primary challenge in selling pre-existing condition insurance lies in distribution channels, as traditional channels are primarily focused on healthy individuals, making it difficult to reach the target demographic [16]. - Collaborations with hospitals are being explored to facilitate access to patients, but these partnerships face regulatory and operational uncertainties [17][18]. - Alternative sales strategies include leveraging pharmaceutical companies' distribution networks, which have shown some success in the market [18]. Group 4: Financial Performance and Risk Management - Currently, the existing pre-existing condition insurance products have not reported losses, but concerns remain regarding the maturity of cost control capabilities [21][22]. - The risk of high claims in million medical insurance products remains a concern, particularly for those that initially relaxed underwriting standards to attract customers [23][24]. - Insurers are employing traditional cost control methods, such as increased premiums and strict underwriting, to manage risks associated with these products [24][25].